Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940742 · ClinicalTrials.gov registry record · Phase 1
A Study of Tirzepatide in Participants With Impaired Liver Function
A Phase 1 study of Hepatic Insufficiency, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT03940742 is a Phase 1 study of Hepatic Insufficiency that has completed, run by Eli Lilly and Company. The registered enrollment target is 32 participants, below the 38-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (16% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03940742, a Phase 1 study of Hepatic Insufficiency, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (3)
California
- Orange County Research Center - Tustin
Florida
- Orlando Clinical Research Center - Orlando
Louisiana
- New Orleans Center for Clinical Research - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2020-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03940742
The ClinicalTrials.gov registry entry for NCT03940742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (16% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT03940742 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03940742 about?
NCT03940742 is a clinical study titled "A Study of Tirzepatide in Participants With Impaired Liver Function". The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
What is the current status of trial NCT03940742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2019-07-22. Estimated completion is 2020-09-22.
What conditions does trial NCT03940742 study?
This clinical trial studies the following conditions: Hepatic Insufficiency.
What interventions are being tested in trial NCT03940742?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT03940742?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03940742 being conducted?
This trial has 3 study locations across California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
RECRUITING · Phase 1
-
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
RECRUITING · Phase 1
-
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
COMPLETED · Phase 1
-
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
COMPLETED · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.